Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $10.80 +0.06 (+0.56%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.76▼$11.0750-Day Range$10.36▼$11.6152-Week Range$8.24▼$13.24Volume3.58 million shsAverage Volume5.93 million shsMarket Capitalization$7.98 billionP/E Ratio2.13Dividend YieldN/APrice Target$17.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Roivant Sciences alerts: Email Address Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside58.3% Upside$17.10 Price TargetShort InterestHealthy8.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.12) to ($1.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.04 out of 5 starsMedical Sector402nd out of 936 stocksPharmaceutical Preparations Industry187th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Roivant Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.37% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 8.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 3.2 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search Interest8 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows9 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($1.12) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesJuly 22, 2024 | techcrunch.comLavish parties and moral dilemmas: 4 days with Silicon Valley’s MAGA elite at the RNCJuly 21, 2024 | yahoo.comLavish parties and moral dilemmas: 4 days with Silicon Valley's MAGA elite at the RNCJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…June 2, 2024 | seekingalpha.comRoivant Sciences: Executing On Huge Buyback Program With More To ComeMay 30, 2024 | investorplace.comROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024May 30, 2024 | globenewswire.comRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateMay 29, 2024 | markets.businessinsider.comRoivant Sciences is about to announce its earnings — here's what Wall Street expectsMay 29, 2024 | uk.news.yahoo.comRamaswamy Urges BuzzFeed to Cut Costs, Air Conservative VoicesJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 29, 2024 | msn.comVivek Ramaswamy pressures BuzzFeed to hire Tucker Carlson and shift to the RightMay 16, 2024 | globenewswire.comRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024May 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 1, 2024 | investorplace.com3 Healthcare Stocks With the Potential to Triple Your Investment by 2026April 25, 2024 | businesswire.comRoivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisApril 24, 2024 | seekingalpha.comRoivant Sciences: Cashing In On Vants And VenturesApril 14, 2024 | markets.businessinsider.comSunrun (RUN) Gets a Buy from RBC CapitalApril 4, 2024 | msn.comRoivant's anti-inflammatory drug shows promise in mid-stage studyApril 2, 2024 | msn.comRoivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease StudySee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/30/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees860Year FoundedN/APrice Target and Rating Average Stock Price Target$17.10 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+58.3%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.06 Trailing P/E Ratio2.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.35 billion Net Margins3,484.86% Pretax Margin3,408.33% Return on Equity-25.05% Return on Assets-20.98% Debt Debt-to-Equity Ratio0.07 Current Ratio25.24 Quick Ratio25.24 Sales & Book Value Annual Sales$124.79 million Price / Sales63.93 Cash FlowN/A Price / Cash FlowN/A Book Value$7.99 per share Price / Book1.35Miscellaneous Outstanding Shares738,720,000Free Float704,741,000Market Cap$7.98 billion OptionableOptionable Beta1.24 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 40)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 37)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 48)President, Chief Investment Officer & Director Comp: $1.72MMr. Richard Pulik (Age 45)Chief Financial Officer Ms. Rakhi Kumar (Age 44)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Jo ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 56)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEDr. Reddy's LaboratoriesNYSE:RDYCatalentNYSE:CTLTQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 58,541 shares on 7/26/2024Ownership: 0.364%EFG Asset Management North America Corp.Bought 34,248 shares on 7/26/2024Ownership: 0.045%Allspring Global Investments Holdings LLCBought 60,221 shares on 7/26/2024Ownership: 0.018%AlphaCentric Advisors LLCSold 2,000 shares on 7/26/2024Ownership: 0.012%Louisiana State Employees Retirement SystemSold 1,300 shares on 7/24/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $11.23 at the start of the year. Since then, ROIV stock has decreased by 3.8% and is now trading at $10.80. View the best growth stocks for 2024 here. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its earnings results on Thursday, May, 30th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. The business earned $28.93 million during the quarter, compared to analyst estimates of $32.46 million. Roivant Sciences had a negative trailing twelve-month return on equity of 25.05% and a net margin of 3,484.86%. Who are Roivant Sciences' major shareholders? Top institutional investors of Roivant Sciences include Bank of New York Mellon Corp (0.36%), Penn Davis Mcfarland Inc. (0.22%), Retirement Systems of Alabama (0.06%) and EFG Asset Management North America Corp. (0.04%). Insiders that own company stock include Pharma Technologies Ltd Dexcel, Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Keith S Manchester, Matthew Gline, Global Investors Lp Viking, Eric Venker, Richard Pulik and Rakhi Kumar. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
